MTS-31: The Mitochondrial-Targeting Peptide Variant in Bioenergetic Research

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is MTS-31?

MTS-31 is a mitochondrial-targeting peptide variant that belongs to the broader class of synthetic peptides designed to selectively accumulate in mitochondria. The designation "MTS" refers to mitochondrial targeting sequence — a structural motif characterized by amphipathic, positively charged peptides that exploit the electrochemical gradient across the inner mitochondrial membrane to achieve selective organelle delivery.

The development of mitochondrial-targeting peptides has been driven by the recognition that mitochondrial dysfunction underlies numerous diseases and aging processes, yet delivering therapeutic agents specifically to mitochondria presents significant pharmacological challenges. Conventional drugs distribute throughout the cell, limiting mitochondrial concentrations and increasing off-target effects. MTS peptides, including MTS-31, represent one approach to overcoming this delivery barrier. For broader context on mitochondrial peptides, see our guide to mitochondrial peptides.

Mechanism of Action

The mechanism of mitochondrial-targeting peptides like MTS-31 is rooted in the biophysics of the mitochondrial membrane potential.

Membrane Potential-Driven Targeting

• Electrochemical gradient: Active mitochondria maintain a substantial membrane potential of approximately -180 mV across the inner mitochondrial membrane (negative inside), generated by the electron transport chain's proton pumping activity. This potential provides a powerful driving force for the accumulation of positively charged molecules.
• Nernst equation prediction: According to the Nernst equation, every unit of positive charge on a molecule results in approximately 10-fold accumulation across the membrane for every 60 mV of potential. With a -180 mV potential, a singly charged cation accumulates ~1,000-fold; doubly charged, ~1,000,000-fold.
• Amphipathic design: MTS peptides are designed to be amphipathic — having both hydrophobic (aromatic) and hydrophilic (cationic) faces. The hydrophobic face facilitates membrane penetration, while the cationic residues drive accumulation against the membrane potential gradient.

Proposed Biological Activities

• ETC interaction: Once accumulated at the IMM, MTS peptides can interact with electron transport chain components and their lipid environment, potentially modulating electron transfer efficiency and ROS production.
• Cardiolipin interaction: Like the related SS-31, MTS peptide variants may interact with cardiolipin, though the specific binding affinity and consequences may differ based on sequence variations.
• Cargo delivery platform: MTS peptides can serve as delivery vehicles, conjugated to therapeutic cargo (antioxidants, enzyme inhibitors, imaging agents) to achieve mitochondrial-targeted delivery.

Research Findings

Structure-Activity Relationships

Research on the SS/MTS peptide series has explored how variations in sequence, charge, and aromatic character affect mitochondrial targeting efficiency and biological activity. Key findings include:

• The alternating aromatic-cationic motif (aromatic-cation-aromatic-cation) is critical for both membrane penetration and mitochondrial accumulation.
• Inclusion of the non-natural amino acid 2',6'-dimethyltyrosine (Dmt) enhanced antioxidant activity and cardiolipin binding compared to natural tyrosine.
• D-amino acid substitutions improve protease resistance without significantly affecting mitochondrial targeting.
• Net charge of +3 appears to be optimal for mitochondrial accumulation without disrupting membrane integrity.

Comparison to SS-31

MTS-31 is studied in the context of optimizing mitochondrial-targeted peptide therapeutics. While SS-31 (elamipretide) has advanced furthest clinically, variations in the MTS peptide series explore whether alternative sequences can offer improved potency, selectivity, or pharmacokinetic properties. The specific advantages or disadvantages of MTS-31 relative to SS-31 remain an area of active investigation, with limited independent published data available.

Critical Assessment

The published literature specifically on MTS-31 is limited compared to the extensive SS-31/elamipretide dataset. Much of the available information is extrapolated from the broader SS peptide series and from general principles of mitochondrial-targeting peptide design. Users should be aware that the evidence base for this specific variant is thin, and claims about its biological activity should be evaluated with appropriate caution.

Safety and Tolerability

Safety data specific to MTS-31 are limited. General principles from the SS peptide series suggest that mitochondrial-targeting peptides are well tolerated at therapeutic concentrations. However, at very high concentrations, cationic peptides can potentially disrupt mitochondrial membrane integrity rather than stabilizing it — a concentration-dependent toxicity window that must be characterized for each specific compound. Formal toxicology studies for MTS-31 have not been published.

Regulatory Status

MTS-31 is not FDA-approved and has not entered clinical trials. It is available through research peptide suppliers for preclinical investigation. For those interested in clinically advanced mitochondrial-targeting peptides, elamipretide (SS-31) represents the furthest-developed compound in this class and provides the most relevant clinical reference point.